BRPI0815611A2 - Processo para sintetizar compostos úteis para tratar hepatite c - Google Patents

Processo para sintetizar compostos úteis para tratar hepatite c

Info

Publication number: BRPI0815611A2
Authority: BR; Brazil
Prior art keywords: compounds useful; treating hepatitis; synthesizing compounds; synthesizing; hepatitis
Prior art date: 2007-08-08

Application number

Other languages

English (en)

Inventor

Shawn K Pack

Peng Geng

Michael J Smith

Jason Hamm

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-08-08

Filing date

2008-07-31

Publication date

2015-03-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39865546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0815611(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-07-31 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2015-03-24 Publication of BRPI0815611A2 publication Critical patent/BRPI0815611A2/pt

2018-08-21 Publication of BRPI0815611B1 publication Critical patent/BRPI0815611B1/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Peptides Or Proteins (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Hydrogenated Pyridines (AREA)
Pyrrole Compounds (AREA)

BRPI0815611-5A 2007-08-08 2008-07-31 Processo para sintetizar compostos úteis para tratar hepatite c BRPI0815611B1 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US95459507P	2007-08-08	2007-08-08
US60/954,595		2007-08-08
PCT/US2008/071696 WO2009020825A1 (en)	2007-08-08	2008-07-31	Process for synthesizing compounds useful for treating hepatitis c

Publications (2)

Publication Number	Publication Date
BRPI0815611A2 true BRPI0815611A2 (pt)	2015-03-24
BRPI0815611B1 BRPI0815611B1 (pt)	2018-08-21

Family

ID=39865546

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0815611-5A BRPI0815611B1 (pt)	2007-08-08	2008-07-31	Processo para sintetizar compostos úteis para tratar hepatite c

Country Status (24)

Country	Link
US (1)	US7728027B2 (pt)
EP (1)	EP2178863B1 (pt)
JP (2)	JP5324574B2 (pt)
KR (1)	KR101528542B1 (pt)
CN (1)	CN101778841B (pt)
AR (2)	AR067896A1 (pt)
AU (1)	AU2008284097B2 (pt)
BR (1)	BRPI0815611B1 (pt)
CA (1)	CA2695711C (pt)
CL (1)	CL2008002355A1 (pt)
CO (1)	CO6251317A2 (pt)
CY (1)	CY1113547T1 (pt)
DK (1)	DK2178863T3 (pt)
EA (1)	EA017173B1 (pt)
ES (1)	ES2396267T3 (pt)
HR (1)	HRP20120990T1 (pt)
IL (1)	IL203685A (pt)
MX (1)	MX2010001415A (pt)
PE (1)	PE20090611A1 (pt)
PL (1)	PL2178863T3 (pt)
PT (1)	PT2178863E (pt)
SI (1)	SI2178863T1 (pt)
TW (1)	TWI423963B (pt)
WO (1)	WO2009020825A1 (pt)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7728027B2 (en) *	2007-08-08	2010-06-01	Bristol-Myers Squibb Company	Process for synthesizing compounds useful for treating hepatitis C
US8629171B2 (en) *	2007-08-08	2014-01-14	Bristol-Myers Squibb Company	Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
KR20100123717A (ko)	2008-02-12	2010-11-24	브리스톨-마이어스 스큅 컴퍼니	Ｃ형 간염 바이러스 억제제로서의 헤테로시클릭 유도체
US7704992B2 (en)	2008-02-13	2010-04-27	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8147818B2 (en)	2008-02-13	2012-04-03	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7906655B2 (en)	2008-08-07	2011-03-15	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8383094B2 (en)	2008-10-01	2013-02-26	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
WO2010075376A2 (en) *	2008-12-23	2010-07-01	Abbott Laboratories	Anti-viral compounds
WO2010075380A1 (en)	2008-12-23	2010-07-01	Abbott Laboratories	Anti-viral compounds
US8394968B2 (en)	2009-02-17	2013-03-12	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8188132B2 (en)	2009-02-17	2012-05-29	Enanta Pharmaceuticals, Inc.	Linked dibenzimidazole derivatives
TWI438200B (zh)	2009-02-17	2014-05-21	必治妥美雅史谷比公司	Ｃ型肝炎病毒抑制劑
US8242156B2 (en)	2009-02-17	2012-08-14	Enanta Pharmaceuticals, Inc.	Linked dibenzimidazole derivatives
WO2010094977A1 (en) *	2009-02-23	2010-08-26	Arrow Therapeutics Limited	Novel biphenyl compounds useful for the treatment of hepatitis c
US8101643B2 (en)	2009-02-27	2012-01-24	Enanta Pharmaceuticals, Inc.	Benzimidazole derivatives
ES2606717T3 (es)	2009-02-27	2017-03-27	Enanta Pharmaceuticals, Inc.	Inhibidores del virus de la hepatitis C
US8673954B2 (en)	2009-02-27	2014-03-18	Enanta Pharmaceuticals, Inc.	Benzimidazole derivatives
US9765087B2 (en)	2009-02-27	2017-09-19	Enanta Pharmaceuticals, Inc.	Benzimidazole derivatives
US8507522B2 (en)	2009-03-06	2013-08-13	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
MX2011010132A (es) *	2009-03-27	2011-10-14	Presidio Pharmaceuticals Inc	Inhibidores de anillo fusionado de hepatitis c.
US8796466B2 (en)	2009-03-30	2014-08-05	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
TW201038559A (en)	2009-04-09	2010-11-01	Bristol Myers Squibb Co	Hepatitis C virus inhibitors
US8143414B2 (en)	2009-04-13	2012-03-27	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
EP2419404B1 (en) *	2009-04-15	2015-11-04	AbbVie Inc.	Anti-viral compounds
RS56654B8 (sr)	2009-05-13	2021-06-30	Gilead Pharmasset Llc	Antiviralna jedinjenja
US8138215B2 (en)	2009-05-29	2012-03-20	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8211928B2 (en)	2009-05-29	2012-07-03	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US9394279B2 (en)	2009-06-11	2016-07-19	Abbvie Inc.	Anti-viral compounds
US8937150B2 (en)	2009-06-11	2015-01-20	Abbvie Inc.	Anti-viral compounds
US8716454B2 (en)	2009-06-11	2014-05-06	Abbvie Inc.	Solid compositions
EA020031B1 (ru) *	2009-06-11	2014-08-29	Эббви Бахамаз Лтд.	Противовирусные соединения
US8221737B2 (en)	2009-06-16	2012-07-17	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8609648B2 (en)	2009-07-02	2013-12-17	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
EP2454254A2 (en)	2009-07-16	2012-05-23	Vertex Pharmaceuticals Incorporated	Benzimidazole analogues for the treatment or prevention of flavivirus infections
EP2473056A4 (en)	2009-09-04	2013-02-13	Glaxosmithkline Llc	CHEMICAL COMPOUNDS
US9156818B2 (en)	2009-09-11	2015-10-13	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8927709B2 (en)	2009-09-11	2015-01-06	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8815928B2 (en)	2009-09-11	2014-08-26	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8703938B2 (en)	2009-09-11	2014-04-22	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8759332B2 (en)	2009-09-11	2014-06-24	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8822700B2 (en)	2009-09-11	2014-09-02	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8415374B2 (en)	2009-10-12	2013-04-09	Bristol-Myers Squibb Company	Combinations of hepatitis C virus inhibitors
US20110269956A1 (en) *	2009-11-11	2011-11-03	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US20110274648A1 (en)	2009-11-11	2011-11-10	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US20110281910A1 (en)	2009-11-12	2011-11-17	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US20110137633A1 (en) *	2009-12-03	2011-06-09	Abbott Laboratories	Anti-viral compounds and methods of identifying the same
TWI429645B (en) *	2009-12-04	2014-03-11		Proline derivatives
US8653070B2 (en)	2009-12-14	2014-02-18	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8377980B2 (en)	2009-12-16	2013-02-19	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
WO2011075607A1 (en) *	2009-12-18	2011-06-23	Intermune, Inc.	Novel inhibitors of hepatitis c virus replication
US8362020B2 (en)	2009-12-30	2013-01-29	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8933110B2 (en)	2010-01-25	2015-01-13	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
CN102843909A (zh)	2010-01-25	2012-12-26	埃南塔制药公司	丙型肝炎病毒抑制剂
US8623814B2 (en)	2010-02-23	2014-01-07	Enanta Pharmaceuticals, Inc.	Antiviral agents
US8178531B2 (en)	2010-02-23	2012-05-15	Enanta Pharmaceuticals, Inc.	Antiviral agents
CN102858157A (zh)	2010-03-04	2013-01-02	埃南塔制药公司	作为hcv复制的抑制剂的组合药物活性剂
MX2012010918A (es)	2010-03-24	2013-01-18	Vertex Pharma	Analogos para el tratamiento o prevencion de infecciones por flavivirus.
WO2011127350A1 (en)	2010-04-09	2011-10-13	Enanta Pharmaceuticals, Inc.	Hepatitis c virus inhibitors
US8778938B2 (en)	2010-06-04	2014-07-15	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
NZ605440A (en)	2010-06-10	2014-05-30	Abbvie Bahamas Ltd	Solid compositions comprising an hcv inhibitor
EP2585447A2 (en)	2010-06-28	2013-05-01	Vertex Pharmaceuticals Incorporated	Compounds and methods for the treatment or prevention of flavivirus infections
JP2013531011A (ja)	2010-06-28	2013-08-01	バーテックスファーマシューティカルズインコーポレイテッド	フラビウイルス感染の処置または予防のための化合物および方法
EP2603080A4 (en)	2010-08-12	2014-01-22	Enanta Pharm Inc	HEPATITIS C-VIRUS HEMMER
US20120195857A1 (en) *	2010-08-12	2012-08-02	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
MX2013001869A (es)	2010-08-17	2013-06-28	Vertex Pharma	Compuestos y metodos para el tratamiento o prevencion de infecciones virales por flaviviridae.
EP2616461A4 (en)	2010-08-26	2014-03-26	Rfs Pharma Llc	POTENTIVE AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS
CN103269586B (zh)	2010-10-26	2015-07-15	普雷西迪奥制药公司	丙型肝炎病毒抑制剂
RU2452735C1 (ru)	2010-11-30	2012-06-10	Александр Васильевич Иващенко	Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
US8552047B2 (en)	2011-02-07	2013-10-08	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US9546160B2 (en)	2011-05-12	2017-01-17	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US10201584B1 (en)	2011-05-17	2019-02-12	Abbvie Inc.	Compositions and methods for treating HCV
EP2709455A4 (en)	2011-05-18	2014-11-05	Enanta Pharm Inc	PROCESSES FOR THE PREPARATION OF 5-AZASPIRO [2.4] HEPTANE-6-CARBOXYLIC ACID AND ITS DERIVATIVES
WO2013016499A1 (en)	2011-07-26	2013-01-31	Vertex Pharmaceuticals Incorporated	Methods for preparation of thiophene compounds
AU2012286853A1 (en)	2011-07-26	2013-05-02	Vertex Pharmaceuticals Incorporated	Thiophene compounds
WO2013030750A1 (en)	2011-09-01	2013-03-07	Lupin Limited	Antiviral compounds
SI2709613T2 (sl)	2011-09-16	2020-12-31	Gilead Pharmasset LLC c/o Gilead Sciences, Inc.	Postopki za zdravljenje HCV
US8466159B2 (en)	2011-10-21	2013-06-18	Abbvie Inc.	Methods for treating HCV
CN104023726A (zh)	2011-10-21	2014-09-03	艾伯维公司	用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
CA2811203C (en)	2011-10-21	2015-05-05	Abbvie Inc.	Methods for treating hcv
US8492386B2 (en)	2011-10-21	2013-07-23	Abbvie Inc.	Methods for treating HCV
US9034832B2 (en)	2011-12-29	2015-05-19	Abbvie Inc.	Solid compositions
US9326973B2 (en)	2012-01-13	2016-05-03	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
IN2014MN01547A (pt)	2012-02-10	2015-05-08	Lupin Ltd
EP2827876A4 (en)	2012-03-22	2015-10-28	Alios Biopharma Inc	PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG
NZ729172A (en)	2013-01-31	2018-06-29	Gilead Pharmasset Llc	Combination formulation of two antiviral compounds
RU2507201C1 (ru)	2013-02-07	2014-02-20	Александр Васильевич Иващенко	Алкил [(s)-1-((s)-2-{5-[4-(4-{2-[(s)-1-((s)-2-метоксикарбониламино-3-метил-бутирил)-пирролидин-2-ил]-3н-имидазол-4-ил}-бута-1,3-диинил)-фенил]-1н-имидазол-2-ил}-пирролидин-1-карбонил)-2-метил-пропил]-карбамат нафталин-1,5-дисульфонат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
TW201526899A (zh)	2013-02-28	2015-07-16	Alios Biopharma Inc	醫藥組成物
US11484534B2 (en)	2013-03-14	2022-11-01	Abbvie Inc.	Methods for treating HCV
US9717712B2 (en)	2013-07-02	2017-08-01	Bristol-Myers Squibb Company	Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en)	2013-07-02	2015-01-22	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
WO2015005901A1 (en)	2013-07-09	2015-01-15	Bristol-Myers Squibb Company	Combinations of hepatitis c virus inhibitors
CN105530933B (zh)	2013-07-17	2018-12-11	百时美施贵宝公司	用于治疗hcv的包含联苯衍生物的组合产品
JP2016529293A (ja)	2013-08-27	2016-09-23	ギリアドファーマセットエルエルシー	２つの抗ウイルス化合物の組合せ製剤
WO2015103490A1 (en)	2014-01-03	2015-07-09	Abbvie, Inc.	Solid antiviral dosage forms
CN104774194B (zh) *	2014-01-09	2018-01-30	正大天晴药业集团股份有限公司	氘代的丙型肝炎病毒抑制剂
CN106279122A (zh) *	2014-01-21	2017-01-04	杭州普晒医药科技有限公司	一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途
CN105524049B (zh) *	2014-09-28	2018-11-06	正大天晴药业集团股份有限公司	氘代的丙型肝炎病毒ns5a蛋白抑制剂
WO2016079697A1 (en) *	2014-11-19	2016-05-26	Sun Pharmaceutical Industries Limited	Process for the preparation of an intermediate of daclatasvir dihydrochloride
WO2016089814A1 (en)	2014-12-02	2016-06-09	Concert Pharmaceuticals, Inc.	Deuterated analogues of daclatasvir
CN105753944B (zh) *	2014-12-19	2019-10-01	正大天晴药业集团股份有限公司	达卡他韦及其衍生物的制备中间体
CN105985227A (zh) *	2015-02-06	2016-10-05	上海特化医药科技有限公司	4,4’-二卤乙酰联苯的制备及应用
CN106188015B (zh) *	2015-05-06	2019-10-18	广东东阳光药业有限公司	一种制备达卡他韦的方法
WO2016178250A1 (en) *	2015-05-07	2016-11-10	Mylan Laboratories Limited	Process for the preparation of daclatasvir
CZ2015366A3 (cs) *	2015-05-29	2016-12-07	Zentiva, K.S.	Pevné formy Daclatasviru
WO2017021904A1 (en) *	2015-08-03	2017-02-09	Laurus Labs Private Limited	Daclatasvir free base and process for the preparation thereof
WO2017023631A1 (en)	2015-08-06	2017-02-09	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
CN105461701A (zh) *	2015-12-14	2016-04-06	上海步越化工科技有限公司	一种抗丙肝新药达卡他韦新的合成方法
CN105622583A (zh) *	2015-12-22	2016-06-01	苏州步跃医药科技有限公司	一种抗丙肝新药达卡他韦新的制备方法
CN105753844A (zh) *	2016-02-16	2016-07-13	江苏苏利精细化工股份有限公司	一种合成二氨基甲酸二甲酯二盐酸盐类化合物的新方法
CN107235965A (zh) *	2016-03-29	2017-10-10	上海医药工业研究院	一种达卡他韦的制备方法
CN107235884B (zh) *	2016-03-29	2021-03-26	上海医药工业研究院	一种达卡他韦中间体及其制备方法
CN105777719A (zh) *	2016-03-29	2016-07-20	安徽联创生物医药股份有限公司	一种达卡他韦的合成方法
JP7129703B2 (ja)	2016-04-28	2022-09-02	エモリーユニバーシティー	アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
CN106256825A (zh) *	2016-07-04	2016-12-28	四川同晟生物医药有限公司	达卡他韦的合成方法
US20190256498A1 (en) *	2016-07-08	2019-08-22	Lupin Limited	Crystalline forms of daclatasvir dihydrochloride
CN106432204A (zh) *	2016-09-12	2017-02-22	上海步越化工科技有限公司	一种抗丙肝达卡他韦的合成方法
CN106496199A (zh) *	2016-10-19	2017-03-15	上海博志研新药物技术有限公司	达卡他韦及其中间体的制备方法
CN108069941A (zh) *	2016-11-15	2018-05-25	广东东阳光药业有限公司	一种制备达卡他韦的方法
CN109305962B (zh) *	2017-07-28	2022-01-18	扬子江药业集团有限公司	一种盐酸达拉他韦的精制方法
CN107501243A (zh) *	2017-09-08	2017-12-22	安徽灵药业有限公司	一种达卡他韦的合成方法
US20220099637A1 (en)	2018-12-04	2022-03-31	Bristol-Myers Squibb Company	Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring
US11442659B2 (en)	2019-11-20	2022-09-13	International Business Machines Corporation	Reading sequentially stored files based on read ahead groups
JP7725617B2 (ja)	2021-05-21	2025-08-19	ギリアードサイエンシーズ，インコーポレイテッド	ジカウイルス阻害剤としての五環式誘導体
CA3219397A1 (en)	2021-05-21	2022-11-24	Gilead Sciences, Inc.	Tetracyclic compounds for the treatment of zika virus infection

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL83467A0 (en) *	1986-08-15	1988-01-31	Fujisawa Pharmaceutical Co	Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
US5654451B1 (en)	1993-01-14	2000-02-22	Magainin Pharma	Amino acids and peptides having modified c-terminals and modified n-terminals
CA2153987A1 (en)	1993-01-14	1994-07-21	U. Prasad Kari	Amino acids and peptides having modified terminals
EP1532118A2 (en) *	2002-07-05	2005-05-25	Axxima Pharmaceuticals Aktiengesellschaft	Imidazole compounds for the treatment of hepatitis c virus infections
GB2438802A (en)	2005-02-28	2007-12-05	Univ Rockefeller	Structure of the hepatitis C virus NS5A protein
US8143288B2 (en) *	2005-06-06	2012-03-27	Bristol-Myers Squibb Company	Inhibitors of HCV replication
AU2006290442B2 (en)	2005-09-16	2010-07-29	Arrow Therapeutics Limited	Biphenyl derivatives and their use in treating hepatitis C
WO2007058384A1 (en)	2005-11-17	2007-05-24	Osaka University	Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same
SG133452A1 (en)	2005-12-30	2007-07-30	Novartis Ag	Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases
EP2038253A1 (en)	2006-05-30	2009-03-25	Arrow Therapeutics Limited	Biphenyl derivatives and their use in treating hepatitis c
US8329159B2 (en) *	2006-08-11	2012-12-11	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7659270B2 (en)	2006-08-11	2010-02-09	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7759495B2 (en)	2006-08-11	2010-07-20	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8236950B2 (en)	2006-12-20	2012-08-07	Abbott Laboratories	Anti-viral compounds
US7728027B2 (en) *	2007-08-08	2010-06-01	Bristol-Myers Squibb Company	Process for synthesizing compounds useful for treating hepatitis C

2008
- 2008-07-17 US US12/174,860 patent/US7728027B2/en not_active Expired - Fee Related
- 2008-07-31 JP JP2010520174A patent/JP5324574B2/ja not_active Expired - Fee Related
- 2008-07-31 EP EP08796910A patent/EP2178863B1/en not_active Not-in-force
- 2008-07-31 BR BRPI0815611-5A patent/BRPI0815611B1/pt not_active IP Right Cessation
- 2008-07-31 CN CN200880102448.7A patent/CN101778841B/zh not_active Expired - Fee Related
- 2008-07-31 PT PT87969101T patent/PT2178863E/pt unknown
- 2008-07-31 DK DK08796910.1T patent/DK2178863T3/da active
- 2008-07-31 MX MX2010001415A patent/MX2010001415A/es active IP Right Grant
- 2008-07-31 AU AU2008284097A patent/AU2008284097B2/en not_active Ceased
- 2008-07-31 EA EA201000300A patent/EA017173B1/ru not_active IP Right Cessation
- 2008-07-31 HR HRP20120990AT patent/HRP20120990T1/hr unknown
- 2008-07-31 SI SI200830878T patent/SI2178863T1/sl unknown
- 2008-07-31 PL PL08796910T patent/PL2178863T3/pl unknown
- 2008-07-31 KR KR1020107002660A patent/KR101528542B1/ko not_active Expired - Fee Related
- 2008-07-31 WO PCT/US2008/071696 patent/WO2009020825A1/en not_active Ceased
- 2008-07-31 ES ES08796910T patent/ES2396267T3/es active Active
- 2008-07-31 CA CA2695711A patent/CA2695711C/en not_active Expired - Fee Related
- 2008-08-08 AR ARP080103487A patent/AR067896A1/es not_active Application Discontinuation
- 2008-08-08 TW TW097130362A patent/TWI423963B/zh not_active IP Right Cessation
- 2008-08-08 PE PE2008001325A patent/PE20090611A1/es not_active Application Discontinuation
- 2008-08-08 CL CL2008002355A patent/CL2008002355A1/es unknown
2010
- 2010-01-29 CO CO10009492A patent/CO6251317A2/es active IP Right Grant
- 2010-02-02 IL IL203685A patent/IL203685A/en active IP Right Grant
2013
- 2013-01-17 CY CY20131100049T patent/CY1113547T1/el unknown
- 2013-07-18 JP JP2013149167A patent/JP2013231072A/ja active Pending
2016
- 2016-12-06 AR ARP160103748A patent/AR106929A2/es unknown

Also Published As

Publication number	Publication date
EA201000300A1 (ru)	2010-06-30
AR067896A1 (es)	2009-10-28
CA2695711A1 (en)	2009-02-12
CN101778841A (zh)	2010-07-14
MX2010001415A (es)	2010-03-01
KR101528542B1 (ko)	2015-06-15
HK1137454A1 (en)	2010-07-30
CY1113547T1 (el)	2016-06-22
DK2178863T3 (da)	2013-02-11
EA017173B1 (ru)	2012-10-30
EP2178863B1 (en)	2012-10-24
ES2396267T3 (es)	2013-02-20
IL203685A (en)	2015-04-30
TW200914441A (en)	2009-04-01
CA2695711C (en)	2014-09-09
CO6251317A2 (es)	2011-02-21
SI2178863T1 (sl)	2013-02-28
JP2010535784A (ja)	2010-11-25
TWI423963B (zh)	2014-01-21
WO2009020825A1 (en)	2009-02-12
BRPI0815611B1 (pt)	2018-08-21
EP2178863A1 (en)	2010-04-28
CL2008002355A1 (es)	2009-01-02
PE20090611A1 (es)	2009-05-16
PT2178863E (pt)	2013-01-14
AU2008284097B2 (en)	2013-01-10
HRP20120990T1 (hr)	2012-12-31
JP2013231072A (ja)	2013-11-14
JP5324574B2 (ja)	2013-10-23
AU2008284097A1 (en)	2009-02-12
PL2178863T3 (pl)	2013-03-29
CN101778841B (zh)	2015-07-22
US7728027B2 (en)	2010-06-01
KR20100045992A (ko)	2010-05-04
US20090043107A1 (en)	2009-02-12
AR106929A2 (es)	2018-02-28

Publication	Publication Date	Title
SI2178863T1 (sl)	2013-02-28	Postopek sintetiziranja spojin uporabnih za zdravljenje hepatitisa C
BRPI0718440A2 (pt)	2013-11-19	Processo de preparo de halogenetos de n-alquinaltrexona
BRPI0816911A2 (pt)	2015-03-17	Processo para preparação de 4-aminobut-2-enolidas
BRPI0910662A2 (pt)	2015-09-29	processo para modificação de superfície de partículas
BRPI0821944A2 (pt)	2015-06-23	Processo
PT2121578T (pt)	2016-11-14	Processo de preparação de ácido 5-bifenil-4-amino-2-metil-pentanoico
BRPI0919868A2 (pt)	2015-12-15	processo
BRPI0910689A2 (pt)	2016-11-01	processo de síntese de rna por via química
BRPI0921374A2 (pt)	2015-12-29	processo
BRPI0810067A2 (pt)	2014-10-21	Processo para a preparação de capecitabina
BRPI0813660A2 (pt)	2014-10-07	Processo para o cultivo de microalgas
BR112012000098A2 (pt)	2014-10-07	Processo para identificação de compostos para tratar câncer
BRPI0921420A2 (pt)	2016-01-05	processo para preparar compostos
BRPI0722077A2 (pt)	2014-04-08	Processo para o acabamento de poliolefina
BRPI0910532A2 (pt)	2015-09-29	processo de síntese de materiais supramoleculares
BRPI0915572A2 (pt)	2017-06-27	processo para a fabricação de epicloroidrina
PT2254850T (pt)	2016-08-29	Processo para iodinação de compostos aromáticos
BRPI0815784A2 (pt)	2015-02-24	Processo para a preparação de 1,2-propanodiol
BRPI0814012A2 (pt)	2015-02-03	Processo para produção de (met)acrilatos
BRPI0911897A2 (pt)	2015-07-28	Processo para a preparação de compostos, e, composto
BRPI0813960A2 (pt)	2015-01-06	Processo para produção de biarilas
BRPI0813764A2 (pt)	2014-12-30	Processo para formação de haletos de carbonila alfa, beta-insaturados
BRPI0815971A2 (pt)	2015-02-18	Processo para a preparação de 1,2-propanodiol
EP2308819A4 (en)	2012-02-29	PROCESS FOR SYNTHESIS OF SEVOFLURANE
BRPI0820300A2 (pt)	2015-05-19	Processo de preparo de compostos morfínicos

Legal Events

Date	Code	Title	Description
2016-03-08	B25A	Requested transfer of rights approved	Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND (CH)
2016-06-14	B65X	Notification of requirement for priority examination of patent application
2016-07-26	B65Y	Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
2016-08-09	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2016-10-18	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2017-05-09	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2017-07-25	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2017-11-21	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2018-04-24	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2018-08-07	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2018-08-21	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
2019-04-09	B25D	Requested change of name of applicant approved	Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITED CO
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/07/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2021-06-01	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 13A ANUIDADE.
2021-09-21	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2630 DE 01-06-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.